Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details)

v3.20.2
License Agreements (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2020
Dec. 31, 2019
Deferred revenue $ 650,000 $ 650,000 $ 1,500,000
BioSense Global LLC [Member]      
Upfront payment   1,650,000  
Amount received from upfront payment   1,550,000  
Deferred revenue 650,000 650,000  
Amount due 100,000 100,000  
Milestone payment 84,500,000 84,500,000  
BioSense Global LLC [Member] | RX-3117 License [Member]      
Upfront payment   750,000  
Revenue recognized   0  
BioSense Global LLC [Member] | RX-3117 Material [Member]      
Revenue recognized 0 900,000  
Zhejiang HaiChang Biotechnology Co., Ltd. [Member]      
Upfront payment   250,000  
Revenue recognized 0 250,000  
Fixed consideration   250,000  
Zhejiang HaiChang Biotechnology Co., Ltd. [Member] | RX-0047 [Member]      
Milestone payment 33,000,000 33,000,000  
Zhejiang HaiChang Biotechnology Co., Ltd. [Member] | RX-0301 And RX-0201 [Member]      
Milestone payment $ 63,000,000 $ 63,000,000